An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Latest Information Update: 22 Jul 2025
At a glance
- Drugs Atezolizumab (Primary) ; INO 5401 (Primary) ; INO 9012 (Primary)
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- Sponsors Inovio Pharmaceuticals
Most Recent Events
- 10 Jul 2025 Status changed from discontinued to completed.
- 21 Nov 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 21 Nov 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.